Susquehanna Fundamental Investments LLC Acquires New Shares in Agenus Inc. (NASDAQ:AGEN)

Susquehanna Fundamental Investments LLC bought a new position in shares of Agenus Inc. (NASDAQ:AGEN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 62,703 shares of the biotechnology company’s stock, valued at approximately $1,050,000. Susquehanna Fundamental Investments LLC owned approximately 0.30% of Agenus as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Point72 DIFC Ltd purchased a new position in shares of Agenus during the 2nd quarter worth approximately $51,000. Ables Iannone Moore & Associates Inc. purchased a new position in Agenus during the fourth quarter worth $65,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Agenus in the second quarter worth $106,000. BNP Paribas Financial Markets lifted its position in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 84,477 shares in the last quarter. Finally, Powell Investment Advisors LLC boosted its stake in shares of Agenus by 21.8% during the first quarter. Powell Investment Advisors LLC now owns 243,500 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 43,500 shares during the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. William Blair downgraded shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. HC Wainwright lowered Agenus from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $40.00 to $9.00 in a research note on Thursday, July 18th. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $7.00 target price (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Agenus currently has an average rating of “Hold” and an average target price of $10.50.

Agenus Stock Down 4.9 %

AGEN stock opened at $4.85 on Thursday. Agenus Inc. has a 52 week low of $4.41 and a 52 week high of $23.20. The company has a market cap of $101.85 million, a price-to-earnings ratio of -0.38 and a beta of 1.36. The business has a fifty day simple moving average of $5.44 and a 200-day simple moving average of $9.84.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The firm had revenue of $23.51 million during the quarter, compared to the consensus estimate of $64.73 million. During the same quarter last year, the business posted ($4.00) EPS. As a group, analysts expect that Agenus Inc. will post -10.87 earnings per share for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.